FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

New Effectiveness Evidence Requirements Analyzed

Two Latham Watkins attorneys analyze a revised FDA draft guidance on demonstrating substantial evidence of effectiveness in drug and biologic trials a...

Human Drugs

Allure Labs FDA-483 Out

FDA releases the form FDA-483 with three observations from an inspection at the Hayward, CA-based Allure Labs drug manufacturing facility.

latest-news-card-1
Human Drugs

Reviewers Concerned About Data Supporting Replimune Melanoma BLA

FDA reviewers raise concerns about the clinical evidence supporting Replimune Group's BLA resubmission for accelerated approval of its investigational...

latest-news-card-1
Medical Devices

Linemaster Switch QS Violations

FDA warns Woodstock, CT-based Linemaster Switch Corp. about Quality System violations in its production of medical device foot pedal accessories.

latest-news-card-1
Human Drugs

FDA: VasoCorp Selling Unapproved, Misbranded Drugs

FDA warns Hiram, GA-based VasoCorp Inc. that it is illegally marketing misbranded unapproved new drugs.

latest-news-card-1
Human Drugs

PhRMA Urges FDA to Clarify Drug Dose Modeling Guidance

The Pharmaceutical Research and Manufacturers of America urges FDA to revise and clarify its draft guidance on using quantitative systems pharmacology...

latest-news-card-1
Human Drugs

Alkem Labs Plant in India Cited Over OOS Investigations, Quality Systems

FDA issues a 26-page Form 483 to Alkem Laboratories following an 4/20-5/1 inspection of the company's finished drug manufacturing facility in Daman, I...

latest-news-card-1
Human Drugs

17 Revised Draft Guidances for Certain Generic Peptide Products

FDA posts 17 revised draft product-specific guidances for peptide products, which it touts as a significant advancement in the agencys scientific and ...

latest-news-card-1
Human Drugs

FDA Accepts for Review Saol Therapeutics SL1009 NDA Resubmission

FDA accepts for review a Saol Therapeutics NDA resubmission for SL1009 (sodium dichloroacetate, or DCA), an investigational treatment for pyruvate deh...

latest-news-card-1
Human Drugs

5 Observations in 17-Page Strides Pharma FDA-483

FDA releases the 17-page form FDA-483 following a May inspection at Indias Strides Pharma Science drug manufacturing facility in Bangalore.